Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASA: Aspirin 81 mg vs 325 mg in Blunt Cerebrovascular Injury
NCT05868525Phase 4Recruiting
- Sponsor
- Loma Linda University
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of aspirin in blunt cerebrovascular injury (BCVI), sponsored by Loma Linda University. Started Aug 2023; status: recruiting.
02
Drugs
aspirin
03
Conditions
blunt cerebrovascular injury (BCVI)
Beyond the preview
Go deeper on NCT05868525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868525.